rss
Evid Based Nurs 8:78 doi:10.1136/ebn.8.3.78
  • Treatment

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations


 
 Q In patients with asthma, is budesonide (BUD) plus formoterol (FORM) (BUDFORM) for both maintenance and symptom relief more effective than fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA), for reducing the rate of severe asthma exacerbations?

METHODS

GraphicDesign:

randomised controlled trial.

GraphicAllocation:

concealed.

GraphicBlinding:

blinded (patients and healthcare providers).

GraphicFollow up period:

1 year

GraphicSetting:

246 centres in 22 countries.

GraphicPatients:

2760 outpatients (mean age 36 y, 55% women/girls; 12% children 4–11 y) with asthma who were using inhaled corticosteroids (ICSs).

GraphicIntervention:

BUDFORM (BUD, 80 μg plus FORM, 4.5 μg) both for maintenance and as needed (BUDFORM for all, n = 925); BUDFORM for maintenance plus terbutaline, 0.4 mg as needed (BUDFORM plus SABA, n = 909); or BUD, 320 …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article